# Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

> **NCT00151242** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Ulm** · enrollment: 920 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Idarubicin
- **DRUG:** Etoposide
- **DRUG:** All-trans retinoic acid
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT00151242
- **Lead sponsor:** University of Ulm
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2011-08
- **Final completion:** 2013-08
- **Target enrollment:** 920 (ACTUAL)
- **Last updated:** 2017-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151242, "Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00151242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*